Christin Melton

Over the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.

Precision, personalized, individualized, targeted — most oncologists are well acquainted with these terms.

The start of 2015 brought news from Novartis that it had signed an agreement with Intellia Therapeutics and Caribou Biosciences to license its proprietary CRISPR/Cas9 gene editing platform to develop novel treatments for chronic genetic-based diseases.